Investigation of the effect of trans-tracheal dexmedetomidine compared to trans-tracheal lidocaine

Comparison of the Efficacy of Trans-Tissue Dexmedetomidine and Trans-Tissue Lidocaine in Patients Undergoing Bronchoalveolar Lavage

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250923067343N3

Enrollment

Registered

2026-05-15

Start date

2026-06-22

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchoalveolar lavage (BAL).

Interventions

Intervention 1: Intervention group: In the lidocaine group, 4 cc of 2% lidocaine and 4 cc of distilled water are prescribed for the patients. Intervention 2: Intervention group: In the dexmedetomidine

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients candidates for Bronchoalveolar Lavage Age between 18 to 65 years

Exclusion criteria

Exclusion criteria: Reluctance to participate in the study

Design outcomes

Primary

Measure	Time frame
Procedure duration. Timepoint: After completion of bronchoalveolar lavage. Method of measurement: Patient file review.;Sedation score. Timepoint: After completion of bronchoalveolar lavage. Method of measurement: Richmond Agitation-Sedation Scale Questioannaire.;Cough score. Timepoint: After completion of bronchoalveolar lavage. Method of measurement: Descriptive rating scale based on assessment of the patient’s clinical symptoms.;Patients tolerance score. Timepoint: After completion of bronchoalveolar lavage. Method of measurement: Assessment of the patient’s clinical symptoms.	—

Measure

Time frame

Procedure duration. Timepoint: After completion of bronchoalveolar lavage. Method of measurement: Patient file review.;Sedation score. Timepoint: After completion of bronchoalveolar lavage. Method of measurement: Richmond Agitation-Sedation Scale Questioannaire.;Cough score. Timepoint: After completion of bronchoalveolar lavage. Method of measurement: Descriptive rating scale based on assessment of the patient’s clinical symptoms.;Patients tolerance score. Timepoint: After completion of bronchoalveolar lavage. Method of measurement: Assessment of the patient’s clinical symptoms.

—

Secondary

Measure	Time frame
Block complications. Timepoint: After completion of bronchoalveolar lavage. Method of measurement: Assessment of patient clinical symptoms.;Secretion amount. Timepoint: After completion of bronchoalveolar lavage. Method of measurement: Assessment of patient clinical symptoms.;Drug complications. Timepoint: After completion of bronchoalveolar lavage. Method of measurement: Assessment of patient clinical symptoms.	—

Measure

Time frame

Block complications. Timepoint: After completion of bronchoalveolar lavage. Method of measurement: Assessment of patient clinical symptoms.;Secretion amount. Timepoint: After completion of bronchoalveolar lavage. Method of measurement: Assessment of patient clinical symptoms.;Drug complications. Timepoint: After completion of bronchoalveolar lavage. Method of measurement: Assessment of patient clinical symptoms.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKobra Rafiei Badi

Shahid Beheshti University of Medical Sciences

abrisham57@gmail.com+98 21 2612 5050

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026